Clinical trials: Essential Hypertension.
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT07704697
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Sacubitril/Allisartan Group
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
- Trial name
- NCT00344110
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 768 people
- Sponsor
- Novartis
Hypertension
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against end organ damage.
- Trial name
- NCT00219037
- Testing
- aliskiren
- Where
- Germany
- Volunteers
- 1,955 people
- Sponsor
- Novartis
Essential Hypertension, Hypercholesterolemia
A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
The purpose of this study is to provide data on the dose response of simvastatin in lowering LDL-C when it is co-administered with valsartan in patients with both essential hypertension and hypercholesterolemia.
- Trial name
- NCT00254475
- Testing
- simvastatin, valsartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 871 people
- Sponsor
- Novartis
Hypertension
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d.
- Trial name
- NCT00250562
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 1,171 people, healthy volunteers welcome
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo.
- Trial name
- NCT00549770
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 182 sites in United States, Argentina and 16 more
- Volunteers
- 1,334 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Postmenopause
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have…
- Trial name
- NCT00102141
- Testing
- Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
- Volunteers
- 750 people
- Sponsor
- Bayer
Hypertension
Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients
The primary objective was to determine the effects of the Gastrointestinal Therapeutic System (GITS) formulation of Doxazosin when used in combination therapy with the 5 major classes of antihypertensive agents as measure by…
- Trial name
- NCT00646841
- Testing
- Doxazosin gastrointestinal therapeutic system (GITS)
- Where
- 7 sites in Italy, Spain and 1 more
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension
In order to confirm the proposed metabolic effect of lacidipine these follow-up study was to provide long-term data on its impact on liver function, glucose homoeostasis and lipid metabolism.
- Trial name
- NCT02177331
- Testing
- Lacidipine
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.
- Trial name
- NCT01848873
- Testing
- Amlodipine, amlodipine-FA tablet, low dose group, amlodipine-FA tablet ,high dose group
- Where
- 16 sites in China
- Volunteers
- 756 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Essential Arterial Hypertension
Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02521246
- Testing
- Candesartan + Chlorthalidone, Losartan+hydrochlorothiazide
- Sponsor
- EMS
Hypertension
Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension
To assess the trough/peak ratio of 40 mg Telmisartan tablet by ambulatory blood pressure monitoring in Chinese patients with mild to moderate essential hypertension
- Trial name
- NCT02206659
- Testing
- Telmisartan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Hypertension,Essential
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
This study was to evaluate the therapeutic effect and safety of Amosartan Plus tablet administration in uncontrolled essential hypertension patients.
- Trial name
- NCT05462535
- Testing
- Amosartan Plus Tab.
- Where
- South Korea
- Volunteers
- 4,785 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
CYT006-AngQb is a vaccine that induces a B-cell mediated immune response characterized by the generation of specific antibodies (IgG and IgM) against Angiotensin II. The vaccine is administered by subcutaneous injection.
- Trial name
- NCT00701649
- Testing
- CYT006-AngQb
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 60 people
- Sponsor
- Cytos Biotechnology AG
High Blood Pressure (Hypertension).
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
The purpose of this research study is to determine if treatment with the combination of metoprolol succinate and hydrochlorothiazide is more effective at lowering blood pressure than treatment with either of the two drugs alone.
- Trial name
- NCT00642096
- Testing
- Metoprolol Succinate, Hydrochlorothiazide
- Volunteers
- 1,900 people
- Sponsor
- AstraZeneca
Hypertension (HTN), NYHA Class III Heart Failure
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to…
- Conditions
- Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure, Diabete Mellitus
- Trial name
- NCT07064525
- Testing
- SPC1001 Low, SPC5002, SPC5003
- Where
- South Korea
- Volunteers
- 252 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Healthy Volunteers Essential Hypertension
Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension.
- Trial name
- NCT06823947
- Testing
- KK3910
- Where
- 3 sites in Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Primary Hypertension
China Stroke Primary Prevention Trial
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.
- Trial name
- CSPPT (NCT00794885)
- Testing
- Enalapril/folic acid, Enalapril maleate
- Where
- 2 sites in China
- Volunteers
- 20,702 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertension
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
The purpose of this study is to compare the effect of the fixed combination of valsartan+hydrochlorothiazide (HCTZ) on blood pressure reduction with valsartan and HCTZ alone and whether the combination treatments are safe and…
- Trial name
- NCT00311740
- Testing
- Valsartan, Hydrochlorothiazide
- Where
- Japan
- Volunteers
- 582 people
- Sponsor
- Novartis